KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

ras oncogenes in human cancer: a review.

1989 • 5,116 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 • 3,698 citations

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 • 3,476 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 • 3,101 citations

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

2004 • 2,674 citations

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

2006 • 2,187 citations

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

2007 • 1,953 citations

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

2008 • 1,579 citations

Cetuximab in the treatment of colorectal cancer.

2004 • 1,501 citations

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

2009 • 1,314 citations

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

2009 • 1,144 citations

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

2007 • 1,111 citations

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

2008 • 832 citations

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

2008 • 735 citations

Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?

2009 • 558 citations

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

2009 • 399 citations

The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma

2005 • 248 citations

Recurrent KRAS codon 146 mutations in human colorectal cancer

2006 • 229 citations

Relationship Among Guanine Nucleotide Exchange, GTP Hydrolysis, and Transforming Potential of Mutated ras Proteins

1988 • 196 citations

Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins.

1988 • 137 citations

Transformation Efficiency of RasQ61 Mutants Linked to Structural Features of the Switch Regions in the Presence of Raf

2007 • 114 citations

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer

2009 • 75 citations

Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM

2008 • 65 citations